000160783 001__ 160783
000160783 005__ 20251017144622.0
000160783 0247_ $$2doi$$a10.1371/journal.pone.0321811
000160783 0248_ $$2sideral$$a143987
000160783 037__ $$aART-2025-143987
000160783 041__ $$aeng
000160783 100__ $$aCarpallo-Porcar, Beatriz
000160783 245__ $$aARACOV-02. Specialized nutritional intervention and telerehabilitation in patients with long COVID: Protocol of a randomized controlled trial
000160783 260__ $$c2025
000160783 5060_ $$aAccess copy available to the general public$$fUnrestricted
000160783 5203_ $$aIt is estimated that at least 10% of the population infected with SARS-CoV-2 develop Post COVID Condition, which is characterized by a diverse array of symptoms including dyspnea, fatigue, anxiety, depression, and deterioration in quality of life. The SARS-CoV-2 virus can trigger an excessive immune response, characterized by the release of pro-inflammatory cytokines including IL-6, IL-1, TNFα and reactive oxygen species. Specialized Pro Resolving Mediators (SPMs) (17-HAD, 14-HAD and 18_HEPE) that could be useful in Post COVID Condition modulating the inflammatory response. The objective is to determine the change in quality of life, inflammatory profile, functional capacity and emotional variables in a group taking a nutritional supplement (SPMs) plus a telerehabilitation programme. Methods. ARACOV-2 study is a double-blind, parallel-group, randomized control trial with two parallel interventions: Nutritional supplement and telerehabilitation vs placebo supplement and telerehabilitation. The primary endpoint will be quality of life (EQ-5L-5D). The intervention will last 12 weeks with a daily intake of omega-3 or placebo and a daily supervised rehabilitation programme using telerehabilitation. Discussion. This study suggests that SPMs supplementation combined with telerehabilitation may improve inflammation and symptoms like fatigue in Post COVID Condition patients. Both interventions have anti-inflammatory potential, and their combined use could enhance physical and mental health outcomes. This approach offers a promising strategy for managing Post COVID Condition symptoms.
000160783 536__ $$9info:eu-repo/grantAgreement/ES/DGA/IDMF 2021-0009
000160783 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000160783 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000160783 700__ $$aJiménez-Sánchez, Carolina
000160783 700__ $$0(orcid)0000-0002-1674-7788$$aCalvo, Sandra$$uUniversidad de Zaragoza
000160783 700__ $$aIrún, Pilar
000160783 700__ $$aKolesnyk-Sumskaya, Elena
000160783 700__ $$aAller-Blanco, Ana Isabel
000160783 700__ $$0(orcid)0000-0001-9815-358X$$aCorral Beamonte, Esther del$$uUniversidad de Zaragoza
000160783 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000160783 7102_ $$11006$$2413$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Fisioterapia
000160783 773__ $$g20, 4 (2025), e0321811 [15 pp.]$$pPLoS One$$tPLoS ONE$$x1932-6203
000160783 8564_ $$s1689131$$uhttps://zaguan.unizar.es/record/160783/files/texto_completo.pdf$$yVersión publicada
000160783 8564_ $$s2206375$$uhttps://zaguan.unizar.es/record/160783/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000160783 909CO $$ooai:zaguan.unizar.es:160783$$particulos$$pdriver
000160783 951__ $$a2025-10-17-14:22:29
000160783 980__ $$aARTICLE